- Dr. Dunton will also serve as an Executive Committee member -
STAMFORD, Conn.—Nov. 19, 2015—Purdue Pharma L.P. today announced the appointment of Alan W. Dunton, M.D. to the position of Senior Vice President of Research & Development (R&D) and will report to Chief Executive Officer Mark Timney. In this role, Dr. Dunton will serve as the Company's lead scientist and will oversee the Medical Research & Drug Safety, Clinical Pharmacology, Virtual Discovery, and Pharmaceutics & Analytics teams.
"At a time of transformation for Purdue, Alan brings the right skills and experience to diversify and grow our portfolio," said Mark Timney, Chief Executive Officer, Purdue Pharma. "We look forward to his contributions in optimizing our existing pipeline, while strengthening our presence in other therapeutic areas."
Dr. Dunton will be responsible for spearheading the Company's overall scientific development strategy, including management of the pipeline, early clinical development programs, and setting the scientific direction for the company.
"Purdue Pharma has a well-established record of innovation in pain medicine that makes a positive impact on patient lives. I look forward to helping the Company continue its pioneering research in pain medicine, as well as innovative research in other areas of unmet need," said Dr. Dunton.
Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue. Prior to starting Danerius, Dr. Dunton held executive-level positions in the pharmaceutical and biotechnology industries, including President and Chief Executive Officer of Panacos Pharmaceuticals and Metaphore Pharmaceuticals. He was also the President and Managing Director of the Janssen Research Foundation, the R&D arm of the pharmaceuticals division at Johnson & Johnson. During his career, Dr. Dunton has been responsible for the approval of more than 20 prescription and OTC products.
Dr. Dunton received his medical doctorate from New York University School of Medicine, where he completed his residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. Dr. Dunton is also a diplomat of the American Board of Internal Medicine and currently licensed to practice medicine in New Jersey and New York. He received his Bachelor of Science degree in biochemistry, magna cum laude, from State University of New York at Buffalo. Dr. Dunton was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his research in medical ethics.
About Purdue Pharma L.P.
Purdue Pharma L.P. is a privately-held pharmaceutical company headquartered in Stamford, Conn. Purdue Pharma is known for pioneering research in the treatment of chronic pain, and is part of a network of independent associated companies dedicated to serving patients and providers with innovative medicines. The company's leadership and employees are dedicated to providing healthcare professionals, patients and caregivers quality products and educational resources that make a positive impact on healthcare — and on lives. With Purdue Pharma's expertise in drug development, commercialization, and life-cycle management, the company is diversifying in high-need areas to expand beyond opioid-based pain treatments through strategic acquisitions and creative partnerships. For more information, please visit www.purduepharma.com or Twitter.
Alan W. Dunton, M.D.
Head of Research & Development
Alan W. Dunton, M.D. joined Purdue Pharma in November 2015 as Senior Vice President of Research & Development (R&D). His responsibilities include spearheading the Company's overall research strategy and early clinical development programs. Dr. Dunton serves as the Company's lead scientist and oversees the Medical Research, Drug Safety, Clinical Pharmacology, Virtual Discovery, Project Management, and Pharmaceutics & Analytics teams.
Dr. Dunton has devoted his 33-year career to the discovery and development of new prescription and over-the-counter (OTC) drug products. In 2006, he founded Danerius LLC, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue Pharma. Prior to starting Danerius, Dr. Dunton held executive-level positions in the pharmaceutical and biotechnology industries, including President and Chief Executive Officer of Panacos Pharmaceuticals and Metaphore Pharmaceuticals. He was also the President and Managing Director of the Janssen Research Foundation, the R&D arm of the pharmaceuticals division at Johnson & Johnson. During his career, he has been responsible for the approval of more than 20 prescription and OTC products.
Dr. Dunton received his medical doctorate from New York University School of Medicine, where he completed his residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. Dr. Dunton is also a diplomat of the American Board of Internal Medicine and currently licensed to practice medicine in New Jersey and New York. He received his Bachelor of Science degree in biochemistry, magna cum laude, from State University of NY at Buffalo. Dr. Dunton was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his research in medical ethics.
The views, opinions and positions expressed within these guest posts are those of the author alone and do not represent those of Becker's Hospital Review/Becker's Healthcare. The accuracy, completeness and validity of any statements made within this article are not guaranteed. We accept no liability for any errors, omissions or representations. The copyright of this content belongs to the author and any liability with regards to infringement of intellectual property rights remains with them.